Filing Flows › Lantheus Holdings (LNTH) › Guidance & outlook
Lantheus Holdings (LNTH) guidance and outlook
Lantheus Holdings' 10-Q filed Nov 5, 2026 makes 27 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- Information contained on our website shall not be deemed incorporated into, or to be part of this Form 10-Q, and any website references are not intended to be made through active hyperlinks.
- Following approval, we intend to continue to support the use of TAUKLARIFY in Alzheimer’s disease therapeutic programs through our Pharma Solutions business while assessing the appropriate path toward broader commercial availability.
- Our approach will remain aligned with the needs of our partners and informed by developments across the Alzheimer’s disease treatment landscape.
- On March 17, 2026, we announced that the FDA has extended its review of the NDA for LNTH-2501, moving the Prescription Drug User Fee Act (“PDUFA”) target action date from March 29, 2026 to June 29, 2026.
- On June 26, 2026, we announced that the FDA issued a CRL in response to the NDA, stating that the agency could not approve the NDA by the June 29, 2026 extended PDUFA target action date due to unresolved third-party facility manufacturing-related conditions.
- We paid $15.0 million of this consideration in July 2026 with the remaining two tranches expected to be paid by the end of 2026, upon satisfaction of certain conditions.
- We plan to work closely with clinicians and PMFs to support a smooth transition, including providing guidance on ordering, handling, and clinical use to support continuity of care.
- We expect to continue to incur costs for the remainder of 2026.
- Heino became our CEO on January 1, 2026 and intended to continue to serve in that role until such time as the Board completes the comprehensive search process that it initiated to identify and appoint the Company’s next CEO.
- The timing, manner, price and amount of any repurchase will be subject to the discretion of our management.
- One of those assets is a leucine-rich repeat-containing protein 15 (“LRRC15”)-targeted monoclonal antibody, which we refer to as LNTH-2403, a clinical therapeutic candidate.
- Under the agreements, we obtained an option to exclusively license Perspective’s Pb212-VMT-α-NET, a clinical stage alpha therapy in development for the treatment of neuroendocrine tumors, and an option to co-develop certain early-stage therapeutic candidates targeting prostate cancer using Perspective’s innovative platform technology for an aggregate upfront payment of $28.0 million in cash.
Lantheus Holdings' latest quarter
Lantheus Holdings, Q3 2026: revenue $390M (+2% year over year), operating margin 8.3%, net earnings $22.4M, operating cash flow $102M. The chart follows the revenue to costs, profit and cash.
Questions
What does Lantheus Holdings expect?
Information contained on our website shall not be deemed incorporated into, or to be part of this Form 10-Q, and any website references are not intended to be made through active hyperlinks. Following approval, we intend to continue to support the use of TAUKLARIFY in Alzheimer’s disease therapeutic programs through our Pharma Solutions business while assessing the appropriate path toward broader commercial availability. Our approach will remain aligned with the needs of our partners and informed by developments across the Alzheimer’s disease treatment landscape.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.